Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease
Open Access
- 12 November 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2447
Abstract
Alzheimer’s disease (AD), the most common cause of dementia, causes irreversible memory loss and cognitive deficits. Current AD drugs do not significantly improve cognitive function or cure the disease. Novel bioproducts are promising options for treating a variety of diseases, including neurodegenerative disorders. Targeting the epigenetic apparatus with bioactive compounds (epidrugs) may aid AD prevention treatment. The aims of this study were to determine the composition of a porcine brain-derived extract Nosustrophine, and whether treating young and older trigenic AD mice produced targeted epigenetic and neuroprotective effects against neurodegeneration. Nosustrophine regulated AD-related APOE and PSEN2 gene expression in young and older APP/BIN1/COPS5 mice, inflammation-related (NOS3 and COX-2) gene expression in 3–4-month-old mice only, global (5mC)- and de novo DNA methylation (DNMT3a), HDAC3 expression and HDAC activity in 3–4-month-old mice; and SIRT1 expression and acetylated histone H3 protein levels in 8–9-month-old mice. Mass spectrometric analysis of Nosustrophine extracts revealed the presence of adenosylhomocysteinase, an enzyme implicated in DNA methylation, and nicotinamide phosphoribosyltransferase, which produces the NAD+ precursor, enhancing SIRT1 activity. Our findings show that Nosustrophine exerts substantial epigenetic effects against AD-related neurodegeneration and establishes Nosustrophine as a novel nutraceutical bioproduct with epigenetic properties (epinutraceutical) that may be therapeutically effective for prevention and early treatment for AD-related neurodegeneration.Keywords
This publication has 119 references indexed in Scilit:
- The role of sirtuins in Alzheimer's diseaseFrontiers in Aging Neuroscience, 2013
- The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related ProteinsJournal of Biological Chemistry, 2013
- Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a reviewJournal of Experimental Pharmacology, 2012
- Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mgJournal of Psychiatric Research, 2012
- The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loopProceedings of the National Academy of Sciences, 2011
- Presenilins and -Secretase: Structure, Function, and Role in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Targeting HDACs: A Promising Therapy for Alzheimer's DiseaseOxidative Medicine and Cellular Longevity, 2011
- Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD miceNeuropharmacology, 2010
- SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosisThe EMBO Journal, 2007
- Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 DeacetylaseScience, 2004